T1	p 25 43	prostatic cancer .
T2	p 159 216	in previously untreated patients with prostatic cancer in
T3	p 623 653	patients with advanced disease
T4	i 243 317	Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate
T5	i 343 355	Stilboestrol
T6	i 363 371	Estracyt
T7	i 473 485	Stilboestrol
T8	i 586 599	gynaecomastia
T9	i 716 751	either Adriamycin or Procarbazine .
T10	o 562 566	side
T11	o 664 674	responsive
T12	o 752 776	Toxicity and early death